SONIDEGIB for Triple negative breast cancer: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 17 adverse event reports in the FDA FAERS database where SONIDEGIB was used for Triple negative breast cancer.
Most Reported Side Effects for SONIDEGIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Muscle spasms | 182 | 12.9% | 8 | 18 |
| Alopecia | 107 | 7.6% | 7 | 9 |
| Off label use | 100 | 7.1% | 2 | 2 |
| Fatigue | 94 | 6.7% | 4 | 7 |
| Death | 87 | 6.2% | 75 | 4 |
| Product use issue | 70 | 5.0% | 1 | 0 |
| Nausea | 69 | 4.9% | 3 | 10 |
| Product dose omission issue | 66 | 4.7% | 0 | 0 |
| Therapy cessation | 64 | 4.5% | 1 | 2 |
| Ageusia | 59 | 4.2% | 1 | 3 |
| Asthenia | 59 | 4.2% | 2 | 15 |
| Decreased appetite | 58 | 4.1% | 2 | 23 |
| Weight decreased | 58 | 4.1% | 3 | 9 |
| Blood creatine phosphokinase increased | 56 | 4.0% | 8 | 14 |
| Diarrhoea | 54 | 3.8% | 9 | 3 |
Other Indications for SONIDEGIB
Basal cell carcinoma (900)
Product used for unknown indication (270)
Myelodysplastic syndrome (25)
Skin cancer (21)
Acute myeloid leukaemia (20)
Medulloblastoma (14)
Neoplasm malignant (14)
Basal cell naevus syndrome (11)
Skin neoplasm excision (11)
Pancreatic carcinoma (10)
Other Drugs Used for Triple negative breast cancer
PEMBROLIZUMAB (5,148)
PACLITAXEL (3,863)
CARBOPLATIN (3,195)
CYCLOPHOSPHAMIDE (1,933)
ATEZOLIZUMAB (1,393)
SACITUZUMAB GOVITECAN-HZIY (1,386)
EPIRUBICIN (1,087)
DOXORUBICIN (967)
DOCETAXEL (691)
SACITUZUMAB GOVITECAN (650)